MicroRNA Expression Profile in CAD Patients and the Impact of ACEI/ARB

• Published in: Cardiology research and practice Vol. 2011; no. 2011; pp. 1 - 5
• Main Authors: Weber, Martina, Baker, Meredith B., Patel, Riyaz S., Quyyumi, Arshed A., Bao, Gang, Searles, Charles D.
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Puplishing Corporation 01-01-2011; SAGE-Hindawi Access to Research; John Wiley & Sons, Inc; Hindawi Limited
• Subjects: Blood circulation; Care and treatment; Clinical Study; Coronary heart disease; Gene expression; Genetic aspects; MicroRNA; Physiological aspects; Properties; United States
• ISSN: 2090-8016; 2090-0597; 2090-0597
• DOI: 10.4061/2011/532915

Coronary artery disease (CAD) is the largest killer of males and females in the United States. There is a need to develop innovative diagnostic markers for this disease. MicroRNAs (miRNAs) are a class of noncoding RNAs that posttranscriptionally regulate the expression of genes involved in important cellular processes, and we hypothesized that the miRNA expression profile would be altered in whole blood samples of patients with CAD. We performed a microarray analysis on RNA from the blood of 5 male subjects with CAD and 5 healthy subjects (mean age 53 years). Subsequently, we performed qRT-PCR analysis of miRNA expression in whole blood of another 10 patients with CAD and 15 healthy subjects. We identified 11 miRNAs that were significantly downregulated in CAD subjects (P<.05). Furthermore, we found an association between ACEI/ARB use and downregulation of several miRNAs that was independent of the presence of significant CAD. In conclusion, we have identified a distinct miRNA signature in whole blood that discriminates CAD patients from healthy subjects. Importantly, medication use may significantly alter miRNA expression. These findings may have significant implications for identifying and managing individuals that either have CAD or are at risk of developing the disease.